Keyphrases
Multicenter Retrospective Study
100%
Non-small Cell Lung Cancer (NSCLC)
100%
Radiomics Signature
100%
Radiomic Biomarker
100%
Stage IB
100%
Biomarkers for Immunotherapy
100%
Area under the Curve
71%
Immune Checkpoint Inhibitors
42%
Substantial Clinical Benefit
42%
Performance Improvement
28%
Predictive Value
28%
Programmed Death-ligand 1 (PD-L1)
28%
CT Images
28%
Tumorous
28%
Radiomics
28%
Pathological Response
28%
Major Pathological Response
28%
Resectable Lung Cancer
28%
Performance Prediction
14%
Nondurables
14%
Online Data
14%
Overall Survival
14%
Progression-free Survival
14%
Survival Outcomes
14%
Model Combining
14%
Radiological Assessment
14%
Non-invasive Biomarkers
14%
Clinical Model
14%
Training Population
14%
Immunotherapy Response
14%
Peritumoral Region
14%
Volume-of-interest
14%
Disease Control
14%
Biological Context
14%
January 2015
14%
Support the Clinical Decision
14%
Clinical Predictors
14%
Non-majors
14%
Response Group
14%
Group Areas
14%
Biomarker Response
14%
Peritumoral
14%
Response Status
14%
Validation Cohort
14%
Predictive Efficacy
14%
Immune Checkpoint Inhibitor Treatment
14%
Tumor-immune System
14%
Immune Landscape
14%
Treatment Response Prediction
14%
Immune Checkpoint Inhibitor Therapy
14%
Medicine and Dentistry
Biological Marker
100%
Retrospective Study
100%
Non Small Cell Lung Cancer
100%
Radiomics
100%
Immunotherapy
100%
Immune Checkpoint Inhibitor
45%
Programmed Cell Death
18%
Neoplasm
9%
Immunity
9%
Overall Survival
9%
Treatment Response
9%
Predictor
9%
Progression Free Survival
9%
Diseases
9%
Immunology and Microbiology
Immunity
100%
Immunotherapy
100%
Cell Death
40%
Overall Survival
20%
Progression Free Survival
20%
Immune Landscape
20%
Biochemistry, Genetics and Molecular Biology
Radiomics
100%
Retrospective Study
100%
Immune Checkpoints
45%
Cell Death
18%
Immunity
9%
Overall Survival
9%
Progression Free Survival
9%
Neuroscience
Immunotherapy
100%
Cell Death
66%
Predictor
33%